EuroBiotech: More Articles of Note

(NS Newsflash/CC BY 2.0)

> GeNeuro posted 12-month data from its Servier-partnered multiple sclerosis phase 2b. The trial missed its primary endpoint last year, but since then the partners have posted data they think support discussions about further development of the asset. Statement

> Shares in Verona Pharma climbed after the company posted data from a phase 2b trial of RPL554 in COPD. The trial linked the dual inhibitor of the phosphodiesterase 3 and 4 to statistically significant improvements in lung function. Release 

> DBV Technologies sold all the additional shares in its global offering, bringing its total gross haul up to $172.5 million (€140.8 million). Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Summit Therapeutics raised £15 million ($21 million). The money will support further development of ezutromid in Duchenne muscular dystrophy. Release

> Auris Medical regained compliance with Nasdaq’s minimum bid price requirement. Statement

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

Kintai Therapeutics' anti-obesity candidate KTX-0200 showed sustained weight loss and improved glucose control and liver health in rodents.

Akcea's triglyceride-fighter beat placebo at lowering blood triglyceride levels in patients who have, or are at risk of, heart disease.